Answer
It is unknown whether vemurafenib passes into human breast milk, and risk to newborns or infants cannot be excluded; discontinuing breast-feeding or vemurafenib therapy must be considered, weighing the benefit of breast-feeding for the child against the benefit of therapy for the woman.
Sources for this answer
- Zelboraf 240 mg Film-coated TabletsRoche Products Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 30Document updated
Sources checked